Gilead ponders Sovaldi price break

Share this article:

Antiviral drugmaker Gilead is rumored to be in price negotiations in India for its new hep. C pill Sovaldi (sofosbuvir). The Hindu Business Line reports that the biotech is looking to introduce Sovaldi into India's marketplace.

Twelve weeks of the treatment costs $84,000 in the US, but the framework for a deal in India is far different: the company is said to be looking to price its locally produced version of the medication at around $2,000 for six months of therapy. The company is in talks with patient advocacy groups.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.